BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 36379125)

  • 1. The impact of tertiary lymphoid structures on clinicopathological, genetic and gene expression characteristics in lung adenocarcinoma.
    Tamiya Y; Nakai T; Suzuki A; Mimaki S; Tsuchihara K; Sato K; Yoh K; Matsumoto S; Zenke Y; Nosaki K; Izumi H; Shibata Y; Sakai T; Taki T; Miyazaki S; Watanabe R; Sakamoto N; Sakashita S; Kojima M; Hashimoto N; Tsuboi M; Goto K; Ishii G
    Lung Cancer; 2022 Dec; 174():125-132. PubMed ID: 36379125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical implications and molecular features of tertiary lymphoid structures in stage I lung adenocarcinoma.
    Xu X; Gao Y; Duan S; Ding Q; Wang X; Dai X; Zhang Y; Chen Y; Chen D
    Cancer Med; 2023 Apr; 12(8):9547-9558. PubMed ID: 36880167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The radiological characteristics, tertiary lymphoid structures, and survival status associated with EGFR mutation in patients with subsolid nodules like stage I-II LUAD.
    Xie M; Gao J; Ma X; Song J; Wu C; Zhou Y; Jiang T; Liang Y; Yang C; Bao X; Zhang X; Yao J; Jing Y; Wu J; Wang J; Xue X
    BMC Cancer; 2024 Mar; 24(1):372. PubMed ID: 38528507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mRNA expression of programmed cell death ligand 1 and components of the phosphatidylinositol 3-kinase/AKT/phosphatase and tensin homolog pathway in epidermal growth factor receptor mutation-positive lung adenocarcinoma.
    Han K; Zhang Y
    J Cancer Res Ther; 2019; 15(4):914-920. PubMed ID: 31436252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship and prognostic significance of IL-33, PD-1/PD-L1, and tertiary lymphoid structures in cervical cancer.
    Zhang Y; Li J; Yang F; Zhang X; Ren X; Wei F
    J Leukoc Biol; 2022 Dec; 112(6):1591-1603. PubMed ID: 35501298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical relevance of PD-L2 expression in surgically resected lung adenocarcinoma.
    Takamochi K; Hara K; Hayashi T; Kohsaka S; Takahashi F; Suehara Y; Shimokawa M; Suzuki K
    Lung Cancer; 2022 Jun; 168():50-58. PubMed ID: 35489160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct Tertiary Lymphoid Structure Associations and Their Prognostic Relevance in HER2 Positive and Negative Breast Cancers.
    Liu X; Tsang JYS; Hlaing T; Hu J; Ni YB; Chan SK; Cheung SY; Tse GM
    Oncologist; 2017 Nov; 22(11):1316-1324. PubMed ID: 28701569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
    Cha YJ; Kim HR; Lee CY; Cho BC; Shim HS
    Lung Cancer; 2016 Jul; 97():73-80. PubMed ID: 27237031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma.
    Siliņa K; Soltermann A; Attar FM; Casanova R; Uckeley ZM; Thut H; Wandres M; Isajevs S; Cheng P; Curioni-Fontecedro A; Foukas P; Levesque MP; Moch H; Linē A; van den Broek M
    Cancer Res; 2018 Mar; 78(5):1308-1320. PubMed ID: 29279354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Impact of Programmed Death-ligand 1 and Surrounding Immune Status on Stage I Lung Cancer.
    Handa Y; Tsutani Y; Shiroma N; Kai Y; Mimae T; Miyata Y; Takeshima Y; Arihiro K; Okada M
    Clin Lung Cancer; 2020 Jul; 21(4):e302-e314. PubMed ID: 32102750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germinal center reactions in tertiary lymphoid structures associate with neoantigen burden, humoral immunity and long-term survivorship in pancreatic cancer.
    J Gunderson A; Rajamanickam V; Bui C; Bernard B; Pucilowska J; Ballesteros-Merino C; Schmidt M; McCarty K; Philips M; Piening B; Dubay C; Medler T; Newell P; Hansen P; Tran E; Tang E; Bifulco C; Crittenden M; Gough M; Young KH
    Oncoimmunology; 2021 Mar; 10(1):1900635. PubMed ID: 33796412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preventive effect of tertiary lymphoid structures on lymph node metastasis of lung adenocarcinoma.
    Wakasu S; Tagawa T; Haratake N; Kinoshita F; Oku Y; Ono Y; Takenaka T; Oda Y; Shimokawa M; Mori M
    Cancer Immunol Immunother; 2023 Jun; 72(6):1823-1834. PubMed ID: 36688996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed death-ligand 1 expression and its associations with clinicopathological features, prognosis, and driver oncogene alterations in surgically resected lung adenocarcinoma.
    Takamochi K; Hara K; Hayashi T; Kohsaka S; Takahashi F; Suehara Y; Suzuki K
    Lung Cancer; 2021 Nov; 161():163-170. PubMed ID: 34600407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors.
    Yang CY; Liao WY; Ho CC; Chen KY; Tsai TH; Hsu CL; Su KY; Chang YL; Wu CT; Hsu CC; Liao BC; Hsu WH; Lee JH; Lin CC; Shih JY; Yang JC; Yu CJ
    Eur J Cancer; 2020 Jan; 124():110-122. PubMed ID: 31760310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer.
    Kim H; Kwon HJ; Park SY; Park Y; Park E; Chung JH
    PLoS One; 2018; 13(6):e0198634. PubMed ID: 29856861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers.
    Hu C; Zhao L; Liu W; Fan S; Liu J; Liu Y; Liu X; Shu L; Liu X; Liu P; Deng C; Qiu Z; Chen C; Jiang Y; Liang Q; Yang L; Shao Y; He Q; Yu D; Zeng Y; Li Y; Pan Y; Zhang S; Shi S; Peng Y; Wu F
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tertiary lymphoid structure score: a promising approach to refine the TNM staging in resected non-small cell lung cancer.
    Rakaee M; Kilvaer TK; Jamaly S; Berg T; Paulsen EE; Berglund M; Richardsen E; Andersen S; Al-Saad S; Poehl M; Pezzella F; Kwiatkowski DJ; Bremnes RM; Busund LR; Donnem T
    Br J Cancer; 2021 May; 124(10):1680-1689. PubMed ID: 33723388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrated analysis of tertiary lymphoid structures in relation to tumor-infiltrating lymphocytes and patient survival in pancreatic ductal adenocarcinoma.
    Tanaka T; Masuda A; Inoue J; Hamada T; Ikegawa T; Toyama H; Sofue K; Shiomi H; Sakai A; Kobayashi T; Tanaka S; Nakano R; Yamada Y; Ashina S; Tsujimae M; Yamakawa K; Abe S; Gonda M; Masuda S; Inomata N; Uemura H; Kohashi S; Nagao K; Kanzawa M; Itoh T; Ueda Y; Fukumoto T; Kodama Y
    J Gastroenterol; 2023 Mar; 58(3):277-291. PubMed ID: 36705749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmed death ligand 1 protein expression is positively correlated with the solid predominant subtype, high MIB-1 labeling index, and p53 expression and negatively correlated with epidermal growth factor receptor mutations in lung adenocarcinoma.
    Yanagawa N; Shiono S; Endo M; Ogata SY; Yamada N; Sugimoto R; Osakabe M; Uesugi N; Sugai T
    Hum Pathol; 2021 Feb; 108():12-21. PubMed ID: 33159965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between Tertiary Lymphoid Structure and the Prognosis and Clinicopathologic Characteristics in Solid Tumors.
    Zhao Z; Ding H; Lin ZB; Qiu SH; Zhang YR; Guo YG; Chu XD; Sam LI; Pan JH; Pan YL
    Int J Med Sci; 2021; 18(11):2327-2338. PubMed ID: 33967609
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.